Dianthus Therapeutics (DNTH) Equity Average (2018 - 2025)

Dianthus Therapeutics' Equity Average history runs 8 years deep, the most recent figure standing at $519.9 million for Q4 2025.

• In Q4 2025, Equity Average rose 50.62% year-over-year to $519.9 million; the TTM figure through Dec 2025 stood at $519.9 million (up 50.62% YoY), while the FY2025 annual figure was $422.9 million, up 62.25% from the prior year.
• Equity Average was $519.9 million for Q4 2025 at Dianthus Therapeutics, up from $424.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $519.9 million in Q4 2025 to a low of -$56.1 million in Q2 2023.
• Historically, Equity Average has averaged $176.4 million across 5 years, with a median of $169.8 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Equity Average tumbled 145.88% in 2022, then surged 750.97% in 2024.
• A 5-year view of Equity Average shows it stood at $86.2 million in 2021, then sank by 145.88% to -$39.6 million in 2022, then surged by 538.88% to $173.6 million in 2023, then surged by 98.81% to $345.2 million in 2024, then jumped by 50.62% to $519.9 million in 2025.
• The last three Equity Average figures came in at $519.9 million (Q4 2025), $424.8 million (Q3 2025), and $315.8 million (Q2 2025), per Business Quant data.